Qualigen aims to change the status quo. Our critical tests take minutes, not days. Treatments should heal, not harm. Qualigen delivers change through science for life.
Qualigen Therapeutics strives to create treatments that propel hope and improved outcomes. We enable patients for healthier tomorrows.
We are unwavering in our commitment to patients & families because we care. Care is at Qualigen’s core across diagnostics and drug development.
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes anti-viral drug compounds such as QN-165 (formerly referred to as AS1411), cancer drug compounds such as QN-247 (formerly referred to as AS1411-GNP or ALAN) and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.